TG Therapeutics
TGTX
431 hedge funds and large institutions have $6.1B invested in TG Therapeutics in 2026 Q2 according to their latest regulatory filings, with 106 funds opening new positions, 147 increasing their positions, 123 reducing their positions, and 35 closing their positions.
203% more first-time investments, than exits
New positions opened: 106 | Existing positions closed: 35
75% more funds holding in top 10
Funds holding in top 10: 4 → 7 (+3)
74% more capital invested
Capital invested by funds: $3.5B → $6.1B (+$2.6B)
65% more call options, than puts
Call options by funds: $163M | Put options by funds: $98.8M
20% more repeat investments, than reductions
Existing positions increased: 147 | Existing positions reduced: 123
18% more funds holding
Funds holding: 365 → 431 (+66)
6.53% more ownership
Funds ownership: 66.03% → 72.56% (+6.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$115M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$87.4M |
| 3 |
Two Sigma Investments
New York
|
+$37.9M |
| 4 |
Barclays
London,
United Kingdom
|
+$34.4M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$30.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$56.7M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$45.1M |
| 3 |
State Street
Boston,
Massachusetts
|
-$35.3M |
| 4 |
ClearBridge Investments
New York
|
-$22.9M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$20.6M |
TGTX Hedge Fund Activity: Q2 2026 in Review
431 of the 8,349 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q2 2026, worth a combined $6.1B — up 74% from $3.5B a quarter earlier.
Buyers outnumbered sellers: 106 funds opened new TGTX positions and 35 closed out — a net gain of 71 holders — while 147 added to existing stakes and 123 trimmed.
The largest buyer was D.E. Shaw & Co, adding an estimated $115M. The largest seller was Citadel Advisors, cutting an estimated $56.7M.
- 431 institutional investors held TG Therapeutics (TGTX) as of Q2 2026, up from 365 in Q1 2026.
- Funds reported $6.1B of TG Therapeutics stock for Q2 2026, up 74% quarter-over-quarter.
- 106 funds opened new TG Therapeutics positions in Q2 2026 and 35 closed out, a net change of +71 holders.
- The largest TG Therapeutics buyer in Q2 2026 was D.E. Shaw & Co, an estimated $115M added.
- The largest TG Therapeutics seller in Q2 2026 was Citadel Advisors, an estimated $56.7M sold.
Based on aggregated 13F filings for Q2 2026.